Kronox Lab Sciences Open Offer Seeks 25.79% at ₹157.27

Kronox Lab Sciences Limited is subject to a ₹150.5 crore cash open offer for up to 95.70 lakh equity shares, or 25.79% of voting share capital, at ₹157.27 per share, following Indo Borax and Chemicals Limited's agreement to acquire a 64.26% promoter stake.

What is the Kronox Lab Sciences open offer?

Kronox Lab Sciences is the target company in a mandatory open offer launched by Indo Borax and Chemicals Limited, with Zenrock Chemicals Private Limited acting as a person acting in concert. The offer seeks to acquire up to 95.70 lakh fully paid-up equity shares from public shareholders at ₹157.27 a share, payable in cash.

At full acceptance, the maximum consideration under the public offer is ₹150.5 crore. IIFL Capital Services Limited is the manager to the open offer and submitted the Letter of Offer to BSE on October 29, 2026. The transaction is being conducted under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Why was the open offer triggered?

The open offer was triggered after Indo Borax and Chemicals and Zenrock agreed to acquire a controlling promoter holding in Kronox Lab Sciences. The share purchase agreement, dated August 20, 2026, covered 2.38 crore shares, representing 64.26% of the company, from three existing promoters.

The promoter-stake transaction was valued at ₹246.1 crore, implying a price of ₹103.22 per share. The open-offer price of ₹157.27 per share is therefore higher than the stated price for the promoter-share transaction. The acquirer's board approved the open offer, while Zenrock is participating alongside Indo Borax as the person acting in concert.

When can shareholders tender Kronox Lab Sciences shares?

The Letter of Offer schedule states that public shareholders can tender their shares from November 6, 2026, through November 20, 2026. Settlement is due within 10 working days after the offer closes, subject to applicable regulations and the required escrow arrangements.

Earlier disclosures had indicated a different proposed schedule, including an October 15 to October 29 tendering window. The October 29 Letter of Offer and the stated November 6 to November 20 tender period provide the later timetable included in the available information. Shareholders should rely on the formal offer documents and exchange disclosures for procedural requirements.

What are the main figures in the Kronox Lab Sciences transaction?

The transaction combines the acquisition of a 64.26% promoter stake with an offer to public shareholders for 25.79% of voting capital. The public offer is capped at 95.70 lakh shares, meaning tenders are subject to the stated offer size and the terms set out in the Letter of Offer.

How does the offer affect Kronox Lab Sciences shareholders and operations?

For public shareholders, the offer creates a defined cash-tender mechanism at ₹157.27 per share. Valid tenders can be accepted up to the maximum offer size, in accordance with the offer conditions and the takeover regulations. The offer is for 25.79% of voting capital, which the disclosures describe as below the 26% minimum requirement under SEBI takeover rules.

Kronox Lab Sciences is required to maintain normal business operations during the offer process and comply with restrictions described under the takeover framework. The reported restrictions include limitations relating to asset sales, borrowings and share issuances while the open-offer process is under way. These requirements are intended to preserve the company's position during a change-of-control transaction.

What has been the market response to the open offer?

A market update cited in the disclosures said Kronox Lab Sciences shares rose more than 10% to ₹205.75 on the BSE after the open-offer announcement. That quoted market price was above the ₹157.27 offer price, illustrating that the market price cited in the update was not aligned with the cash offer price.

The key financial consideration is the difference between the promoter-sale price of ₹103.22 per share and the public open-offer price of ₹157.27 per share. The open offer also gives investors a scheduled exit route, but participation, acceptance and settlement remain governed by the Letter of Offer, tender process and SEBI regulations.

Conclusion

The Kronox Lab Sciences transaction involves a change in control through Indo Borax's proposed acquisition of a 64.26% promoter stake, followed by a ₹150.5 crore open offer for up to 25.79% of the company's voting share capital. The offer price is ₹157.27 per share in cash, and IIFL Capital Services is managing the process.

The next disclosed milestone is the tendering window from November 6 to November 20, 2026. Shareholders will need to track the formal tender instructions, acceptance process and settlement timeline, which is scheduled within 10 working days after the offer closes, subject to regulatory and escrow conditions.